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cathelicidin Downregulation in 
Dendritic cells and allows Th1 
Differentiation and iFn  secretionγ
Anna K. O. Rode†, Martin Kongsbak†, Marie M. Hansen, Daniel Villalba Lopez,  
Trine B. Levring, Anders Woetmann, Niels Ødum, Charlotte M. Bonefeld  
and Carsten Geisler*
Faculty of Health and Medical Sciences, Department of Immunology and Microbiology, University of Copenhagen, 
Copenhagen, Denmark
Tuberculosis (TB) presents a serious health problem with approximately one-third of the 
world’s population infected with Mycobacterium tuberculosis in a latent state. Experience 
from the pre-antibiotic era and more recent clinical studies have established a beneficial 
role of sunlight and vitamin D in patients with TB. At the same time, experimental data 
have shown that Th1 cells through production of IFNγ are crucial for cathelicidin release 
by macrophages, bacterial killing, and containment of M. tuberculosis in granulomas. 
Paradoxically, vitamin D has repeatedly been ascribed an immune-suppressive function 
inhibiting Th1 differentiation and production of IFNγ in T cells. The aim of this study was 
to investigate this apparent paradox. We studied naïve human CD4+ T cells activated 
either with CD3 and CD28 antibodies or with allogeneic dendritic cells (DC) stimulated 
with heat-killed M. tuberculosis (HKMT) or purified toll-like receptor (TLR) ligands. We 
show that vitamin D does not block differentiation of human CD4+ T cells to Th1 cells 
and that interleukin (IL)-12 partially counteracts vitamin D-mediated inhibition of IFNγ 
production promoting production of equal amounts of IFNγ in Th1 cells in the presence 
of vitamin D as in T cells activated in the absence of vitamin D and IL-12. Furthermore, 
we show that HKMT and TLR2 ligands strongly downregulate cathelicidin expression in 
DC and that vitamin D counteracts this by upregulating cathelicidin expression. In con-
clusion, we demonstrate that vitamin D counteracts M. tuberculosis-induced cathelicidin 
downregulation and allows Th1 differentiation and IFNγ secretion.
Keywords: vitamin D, tuberculosis, T cells, dendritic cells, Th1, iFnγ, cathelicidin
inTrODUcTiOn
Tuberculosis (TB) presents a serious health problem with more than 10 million new cases of active TB 
responsible for 1.8 million deaths in 2015 (1). The disease is caused by the pathogen Mycobacterium 
tuberculosis. It is presumed that approximately one-third of the world’s population is infected with 
M. tuberculosis in an asymptomatic latent state and that 5–10% of infected individuals develops 
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active TB at some point in their lives either shortly after initial 
infection or as a progression from a latent infection (2). Children 
and individuals with an impaired immune system generally have 
a higher risk of developing active TB (3).
M. tuberculosis is transmitted through aerosol droplets to the 
lung alveoli, where the pathogen infects alveolar macrophages 
and subsequently dendritic cells (DC), neutrophils, and 
macrophages in the lung interstitium (4). Activation of naïve 
TB-specific T  cells depends on the migration of infected DC 
from the lungs to the mediastinal lymph nodes (5–7). DC present 
M. tuberculosis antigens for the T  cells and dependent on the 
cytokines present during the T cell receptor-mediated activation 
process, the CD4+ T helper (Th) cells differentiate to different 
types of effector cells in the lymph nodes (8, 9). Macrophages 
and DC become activated by stimulation through the toll-like 
receptors (TLR)2, 4, and 9 in response to M. tuberculosis and start 
production of pro-inflammatory cytokines such as tumor necro-
sis factor α (TNFα), interleukin (IL)-1β, and IL-12 (10). IL-12 
plays a major role in the differentiation of Th cells to interferon 
γ (IFNγ)-producing Th1 effector cells by signaling through the 
IL-12 receptor (IL-12R), which results in phosphorylation and 
dimerization of signal transducer and activator of transcription 
(STAT)4. STAT4 then translocates to the nucleus and binds to 
regulatory elements of target genes, including the Th1 master 
transcription factor TBX21, IL12Rβ2, and IFNG. IFNγ induces 
phosphorylation of STAT1 that further activates transcription of 
TBX21 and IL12Rβ2, which in turn act in a positive-feedback 
loop to amplify Th1 differentiation (8, 9). The resulting Th1 effec-
tor cells migrate out of the lymph nodes and are then recruited to 
the sites of infection.
In the latent state, M. tuberculosis is contained by the immune 
system in granulomas consisting mainly of infected macrophages 
surrounded by IFNγ-producing Th1  cells (2, 11). The impor-
tance of IFNγ in the immune response to mycobacteria is well 
established in both humans and mice. Thus, individuals with 
a mutation in genes related to the production of or response 
to IFNγ have a high susceptibility to mycobacterial infection 
(12–16). Likewise, mice that lack IFNγ or the IFNγ receptor are 
extremely susceptible to TB (17, 18). IFNγ is crucial for activa-
tion of macrophages and the formation and containment of 
M. tuberculosis in granulomas (13, 18). A central role of IFNγ is 
to enhance the ability of macrophages to kill intracellular patho-
gens such as M. tuberculosis (19, 20). The antimicrobial peptide 
cathelicidin plays an important role in the ability of macrophages 
to kill bacteria, and it has been reported that IFNγ increases the 
expression of cathelicidin in human monocytes and macrophages 
(21–23). Interestingly, these studies found that vitamin D is 
required for IFNγ-mediated enhancement of cathelicidin. This is 
in good agreement with several studies showing that vitamin D 
deficiency is associated with impaired expression of cathelicidin 
and increased susceptibility to infectious diseases, including TB 
(24–30), and it could be an important mechanism explaining the 
beneficial role of vitamin D in TB prevention and treatment (31, 
32). In sharp contrast to this, several studies have shown that 
vitamin D inhibits the production of IFNγ in T cells (33–46). This 
creates a significant paradox in which vitamin D is required for 
efficient innate immune responses against M. tuberculosis but at 
the same time impairs Th1-mediated immune responses against 
M. tuberculosis.
The aim of this study was to look deeper into this apparent 
paradox and to determine whether vitamin D actually impedes 
Th1 differentiation and how vitamin D affects IFNγ production 
in Th1 cells and cathelicidin production in DC.
MaTerials anD MeThODs
chemicals
25(OH)D3 (BML-DM-100-0001) and 1,25(OH)2D3 (BML- 
DM200-0050) were from Enzo Life Sciences, Inc., Ann Arbor, 
MI, USA. Stock solutions of 2.5  mM 25(OH)D3 and 2.4  mM 
1,25(OH)2D3 were prepared in anhydrous (≥99.5%) ethanol and 
stored at −20°C. To determine 1,25(OH)2D3 in the supernatants, 
we used the 1,25-dihydroxy vitamin D EIA kit (AC-62F1) 
from IDS, Tyne and Wear, UK according to the manufacturer’s 
instructions.
cell culture
Mononuclear cells from blood were isolated by Lymphoprep 
(Axis-Shield, Oslo, Norway) density-gradient centrifugation 
using SepMate™ tubes (86460, Stemcell Technologies, Grenoble, 
France) from healthy donors after obtaining informed, writ-
ten consent in accordance with the Declarations of Helsinki 
principles for research involving human objects. The study was 
approved by The Committees of Biomedical Research Ethics 
for the Capital Region in Denmark (H-16033682). Naïve CD4+ 
T cells were isolated and cultured as previously described (47). 
The purified naïve CD4+ T  cells were cultured in serum-free 
X-VIVO 15 medium (BE02-060F, Lonza, Verviers, Belgium) at 
37°C, 5% CO2 at a cell concentration of 1 × 106 cells/ml in flat-
bottomed 24-well tissue culture plates (142475) from Nunc and 
stimulated with Dynabeads human T-activator CD3/CD28 beads 
(111.31D, Life Technologies, Grand Island, NY, USA) at a cell to 
bead ratio of 5:2 for up to 3 days. Cells present in the culture after 
3  days were defined as activated T  cells. In some experiments, 
25(OH)D3, 1,25(OH)2D3, or recombinant human IL-12 (219-IL, 
R&D Systems) was added at the indicated concentrations to 
the medium during the stimulation period. In Th1 polarization 
studies, purified naïve CD4+ T cells were cultured and stimulated 
as described above in the presence of recombinant human IL-12 
(10 ng/ml) plus human IL-4 antibody (4 µg/ml, MAB204, R&D 
Systems). In some experiments, cells were counted after 72  h 
of activation using the automated cell counter NucleoCounter® 
NC-100™ from Chemometec.
Monocytes used for generation of monocyte-derived DC were 
isolated from blood mononuclear cells using EasySep Human 
Monocyte Enrichment Kit (19059, Stemcell Technologies) 
according to the manufacturer’s protocol. Following isolation, 
monocytes were cultured in flat-bottomed six-well tissue culture 
plates (140675, Nunc) at a cell concentration of 5 × 105 cells/ml 
for 6 days in medium (RPMI-1640, R5886, Sigma-Aldrich) with 
penicillin, streptomycin, l-glutamine, and 10% heat-inactivated 
FBS (10082-147, Gibco) supplemented with GM-CSF and IL-4 
(both 50 ng/ml, AF-HDC, PeproTech) with a re-supplementation 
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of medium and cytokines on day 3. On day 5, the differentiated 
DCs were supplemented with GM-CSF (50 ng/ml) and treated 
with either heat-killed M. tuberculosis (HKMT) (10 µg/ml, tlrl-
hkmt, InvivoGen), Pam3CSK4 (300 ng/ml, tlrl-pms, Invivogen) 
as TLR2 ligand, lipopolysaccharides (LPS) from E. coli (50 ng/ml, 
L 5668, Sigma) as TLR4 ligand, or left untreated for 24 h, washed, 
and resuspended in X-VIVO 15 medium for use in mono- and 
co-cultures or in RPMI-1640 medium for use in 1,25(OH)2D3 
titration experiments. For monocultures, 2.5–5 ×  105 cells/ml 
DC were plated in flat-bottomed 24-well tissue culture plates for 
24 h in the presence or absence of 25(OH)D3 and with or without 
recombinant human IFNγ (R&D Systems) or with increasing 
concentrations of 1,25(OH)2D3 for titration studies. For co-culture 
studies, naïve human CD4+ T cells were purified from a different 
donor as described above and co-cultured with 1 × 105 cells/ml 
DC in a ratio of 1:10 DC to T cells in flat-bottomed 24-well tissue 
culture plates for another 6 days in X-VIVO 15 medium.
elisa
IFNγ and IL-13 concentrations in the supernatants were 
determined by ELISA according to the manufacturer’s protocol 
(Ready-Set-Go; eBioscience).
QPcr
mRNA expression was measured by real-time RT-PCR (QPCR). 
For this, cells were lysed in TRI reagent (T9424, Sigma-Aldrich) 
followed by addition of 1-bromo-3-chloropropane (B9673, 
Sigma Aldrich) to separate the sample into an aqueous and an 
organic phase. The RNA was precipitated from the aqueous phase 
using isopropanol supplemented with glycogen (10814-010, 
Invitrogen), washed with ethanol, and dissolved in RNase free 
water. Equal amounts of total RNA were used for complemen-
tary DNA (cDNA) synthesis using the high-capacity RNA-to-
cDNA™ Kit from Applied Biosystems (4387406) according to 
manufacturer’s protocol. For QPCR, 12.5 ng cDNA was mixed 
with TaqMan® Universal Master Mix II with UNG (4440038, 
Applied Biosystems), the target primer, and the eukaryotic 
18 S rRNA primer (1509311, Applied Biosystems). The samples 
were run on a Stratagene Mx3000P™ real-time PCR machine 
(Agilent Technologies). The thermal profile was set to 2 min at 
50°C, a 10  min hot start at 95°C, followed by cycles of 15  s at 
95°C and 1 min at 60°C. Signal intensity was measured at the end 
of the 60°C step, and the threshold cycle values were related to 
eukaryotic 18S rRNA. The following primers were used; IFNG 
(Hs00989291_m1), CYP27B1 (Hs01096154_m1), vitamin D 
receptor (VDR) (Hs01045840_m1), CYP24A1 (Hs00167999_
m1), TBX21 (Hs00203436_m1), IL-12RB2 (Hs00155486_m1), 
CXCL9 (Hs00171065_m1), CXCL10 (Hs00171042_m1), and 
CAMP (cathelicidin antimicrobial peptide) (Hs00189038_m1) 
all from Applied Biosystems.
Western Blot analysis
For Western blot analysis, whole cell lysates were obtained 
by treatment of the cells with lysis buffer (50 mM Tris pH 7.5, 
150  mM NaCl, 1  mM MgCl2) supplemented with 1% Triton 
X-100, 1× Protease inhibitor cocktail (5872S, Cell Signaling 
Technology, Beverly, MA, USA) and 5 mM EDTA. The samples 
were run under reducing conditions on polyacrylamide gels for 
2 h at 120 volt in 1× NuPAGE MOPS SDS Running buffer (K855, 
Amresco, Solon, OH, USA) in an XCell SureLock® Mini-Cell 
Module from Life Technologies. The proteins were transferred to 
nitrocellulose membrane sheets (LC2001, Life Technologies) in 
1× NuPAGE Transfer buffer (NP0006-1, Life Technologies) sup-
plemented with 10% ethanol for 60 min at 50 V in an XCell II™ 
Blot Module from Life Technologies. The membranes were subse-
quently blocked for 60 min in Tris-buffered saline supplemented 
with 5% milk powder (70166, Sigma-Aldrich) and 0.1% Tween 
20 (P1379, Sigma-Aldrich) and incubated at 4°C for 24 h with 
primary antibodies diluted in Tris-buffered saline supplemented 
with 5% bovine serum albumin (A4503, Sigma-Aldrich) and 
0.1% Tween 20. The membranes were washed and the proteins 
visualized following 60 min incubation at room temperature with 
secondary HRP-rabbit anti-mouse Ig and HRP-swine anti-rabbit 
Ig using ECL (RPN2232, Sigma Aldrich) technology. The anti-
phospho-STAT1 (9171) and phospho-STAT4 (5267) antibodies 
were from Cell Signaling Technologies, the anti-STAT1 (SC-
346), STAT4 (SC-486), and VDR (SC-13133) antibodies were 
from Santa Cruz Biotechnology, Santa Cruz, CA, USA and the 
anti-GAPDH (Ab9485) was from Abcam, Cambridge, UK. For 
band density quantification, ECL-exposed sheets were analyzed in 
a ChemiDoc MP Imaging System from Bio-Rad.
statistical analysis
Data are shown as mean ±  SEM. Statistical analyses were per-
formed using Student’s t-test with a 5% significance level, paired 
observations, and equal variance. * indicates p ≤ 0.05.
resUlTs
il-12 Partially counteracts Vitamin 
D-Mediated inhibition of iFnγ Production 
in cD4+ T cells
Most previous studies on the effect of vitamin D on IFNγ 
production in human T cells have been performed using heter-
ologous cell populations or purified CD4+ T cells in cell culture 
medium supplemented with serum and non-physiological, 
high concentrations (1–100 nM) of the active form of vitamin 
D (1,25(OH)2D) (41–45). Various sources of serum contain 
different concentrations of the inactive form of vitamin D 
(25(OH)D), 1,25(OH)2D, and the vitamin D-binding protein, 
all of great importance when investigating the effect of vitamin 
D on T  cells (24, 46). To study the direct effect of 25(OH)D3 
and 1,25(OH)2D3 on IFNγ production in human Th cells under 
strictly defined conditions, we isolated naïve CD4+ T cells and 
stimulated them with human T-activator CD3/CD28 beads in 
serum-free medium in the absence or presence of 25(OH)D3 
or 1,25(OH)2D3. We found that 1,25(OH)2D3 strongly inhibited 
IFNγ production (~15-fold) at physiological concentrations 
(60–110 pM) (Figure 1A). Furthermore, we found that 25(OH)
D3 at physiological concentrations (50–125 nM) inhibited IFNγ 
production to the same degree as 1,25(OH)2D3 (Figure  1A), 
which confirms that T cells have the ability to convert the inactive 
25(OH)D3 to the active 1,25(OH)2D3 (46, 47). It is well known 
FigUre 1 | IL-12 counteracts vitamin D-mediated inhibition of IFNγ 
production in CD4+ T cells. (a) IFNγ concentration in the supernatants of 
T cells activated for 72 h in the presence of the indicated concentrations of 
25(OH)D3 or 1,25(OH)2D3. Representative graphs from two independent 
experiments with three donors are shown. (B) Number of CD4+ T cells in the 
cell cultures after activation for 72 h in the presence or absence of 100 nM 
25(OH)D3 relative to initial cell number (mean + SEM, n = 12). (c) IL-13 
concentration in the supernatant of T cells activated for 72 h in the presence 
of the indicated concentrations of 25(OH)D3 (mean ± SEM, n = 6). (D) IFNγ 
concentration in the supernatants of T cells activated for 72 h in the presence 
of the indicated concentrations of 25(OH)D3 and IL-12 (mean + SEM, n ≥ 4).
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that anti-CD3/CD28 bead stimulation promotes expansion of 
CD4+ T cells (48). To investigate whether the lower levels of IFNγ 
in vitamin D-treated cells could be attributed to fewer cells, we 
stimulated CD4+ T cells for 72 h in the presence or absence of 
100 nM 25(OH)D3 and subsequently counted the cells using an 
automated cell counter. At this time point, we found that there 
were approximately 1.5-fold more CD4+ T cells in the cultures 
compared to the initial cell number independently of the absence 
or presence of vitamin D (Figure 1B). To exclude a general toxic 
effect of vitamin D on the T  cells, we subsequently measured 
secretion of IL-13 in parallel with IFNγ. We found that vitamin 
D increased IL-13 secretion in parallel with its inhibition of IFNγ 
secretion (Figure 1C). Thus, the decreased levels of IFNγ were 
not caused by a reduced cell number or a toxic effect of vitamin 
D but most likely by a specific effect of vitamin D on IFNγ secre-
tion. Previous studies have reported that 1,25(OH)2D3 inhibits 
production of IFNγ and augment the production of IL-4, and 
based on these observations it has been concluded that vitamin 
D restrains Th1 differentiation and promotes Th2 differentiation 
(41–45). However, to our knowledge, the effect of physiologi-
cal concentrations of vitamin D on IFNγ production in T cells 
activated under Th1-inducing conditions has not been reported. 
To study this, we activated naïve CD4+ T cells in the absence or 
presence of IL-12 and 25(OH)D3. In the absence of 25(OH)D3, 
IL-12 increased IFNγ production (Figure  1D). Interestingly, 
although 25(OH)D3 at physiological concentrations did reduce 
IFNγ production in IL-12 treated cells, these cells still produced 
equal amounts of IFNγ as T  cells activated in the absence of 
25(OH)D3 and IL-12 (Figure 1D). From these experiments, we 
could conclude that 1,25(OH)2D3 inhibits the production of IFNγ 
in CD4+ effector T  cells but that IL-12 partially rescues IFNγ 
production in the presence of vitamin D allowing production of 
similar amounts of IFNγ as in T cells activated in the absence of 
vitamin D and IL-12.
il-12 Does not inhibit 1,25(Oh)2D3 
Production or VDr expression and 
Function in cD4+ T cells
One way for IL-12 to counteract vitamin D-mediated inhibi-
tion of IFNγ production in CD4+ T  cells could be by limiting 
the ability of the cells to convert 25(OH)D3 to 1,25(OH)2D3. To 
investigate this, we studied whether IL-12 affected the expression 
of CYP27B1, the enzyme responsible for converting 25(OH)D3 
to 1,25(OH)2D3. We activated naïve CD4+ T cells in the presence 
of 100  nM 25(OH)D3 in the absence or presence of IL-12 and 
measured the expression levels of CYP27B1 mRNA in the cells. 
We found that IL-12 did not influence the expression of CYP27B1 
(Figure 2A). Furthermore, we directly measured the production 
of 1,25(OH)2D3 in the supernatants and found that IL-12 did not 
affect the production of 1,25(OH)2D3 (Figure 2B). Another way 
IL-12 might counteract vitamin D-mediated inhibition of IFNγ 
production in CD4+ T cells could be by inhibiting the expression 
or function of the VDR. However, we found that IL-12 slightly 
increased VDR expression on the mRNA level (Figure 2C). To 
further investigate whether IL-12 affected VDR expression, we 
determined the effect of IL-12 on VDR protein levels. We did 
not observe any significant effect of IL-12 on VDR expression 
at the protein level (Figure  2D). CYP24A1 is the enzyme that 
initiates degradation of 1,25(OH)2D3, and CYP24A1 expres-
sion is dependent on functional 1,25(OH)2D3/VDR complexes. 
Consequently, we measured the CYP24A1 levels in cells treated 
with or without IL-12. We found that the cells produced very 
high amounts of CYP24A1 in the presence of 100 nM 25(OH)D3 
(approximately 100.000-fold upregulated compared to unstimu-
lated T cells) although IL-12 slightly reduced CYP24A1 expres-
sion (Figure  2E). Taken together, these experiments indicated 
that IL-12 does not counteract vitamin D-mediated inhibition 
of IFNγ production in CD4+ T cells by reducing their ability to 
FigUre 2 | IL-12 does not inhibit 1,25(OH)2D3 production or VDR expression 
and function in CD4+ T cells. Relative CYP27B1 (a), VDR (c), and CYP24A1 
(e) expression in T cells activated for 72 h in the presence of 100 nM 25(OH)
D3 and the indicated concentration of IL-12. Data are normalized to activated 
T cells incubated with 100 nM 25(OH)D3 in the absence of IL-12 
(mean + SEM, n ≥ 6). (B) 1,25(OH)2D3 production in T cells activated for 72 h 
in the presence of 100 nM 25(OH)D3 and the indicated concentration of IL-12 
(mean + SEM, n ≥ 4). (D) Representative Western blot (lower panel) and 
quantification (upper panel) of VDR with GAPDH as loading control from 
T cells activated for 72 h in the presence of 100 nM 25(OH)D3 and in the 
presence or absence of 10 ng/ml IL-12 (mean + SEM, n = 4). Western blots 
including protein ladder are shown in the Figure S1 in Supplementary 
Material.
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produce 1,25(OH)2D3 or by reducing their VDR expression or 
function.
Vitamin D Does not Prevent Th1 
Differentiation
Due to the inhibition of IFNγ production, it has been suggested that 
vitamin D impedes differentiation of Th1 cells. However, whether 
vitamin D actually inhibits Th1 differentiation is still not known. 
To directly study whether vitamin D affects Th1 differentiation, 
we stimulated naïve CD4+ T cells under classical Th1 conditions 
with IL-12 and anti-IL-4 in the absence or presence of 25(OH)
D3 and measured the expression levels of TBX21 and IL-12Rβ2. 
Compared to naïve T cells, cells activated for 24 h in the absence of 
25(OH)D3 upregulated TBX21 approximately 120-fold. Although 
not significantly, 25(OH)D3 slightly reduced TBX21 upregulation 
at 24 h but had no inhibitory effect on TBX21 expression after 48 
and 72 h (Figure 3A). Likewise, IL-12Rβ2 expression was slightly 
reduced after 24 h but unaffected by 25(OH)D3 after 48 and 72 h 
of stimulation (Figure 3B). While vitamin D did not affect TBX21 
and IL-12Rβ2 expression in cells stimulated for 48 and 72 h, it 
clearly reduced IFNγ expression in the same cells (Figure 3C). 
Thus, these experiments indicated that vitamin D does not block 
differentiation of Th1 cells but directly affects the transcription of 
the IFNG gene. Although reduced, IFNγ expression in Th1 cells 
treated with vitamin D was still highly upregulated (1000- to 
2000-fold, Figure  3C) and they produced high levels of IFNγ 
(Figure  1D). In line with the strong production of IFNγ, we 
found that vitamin D did not affect STAT1 phosphorylation 
significantly during T  cell activation (Figure  3D). Likewise, 
STAT4 phosphorylation was not significantly affected of vitamin 
D (Figure 3E).
IFNγ itself plays an important role during Th1 differentiation 
as STAT1 activated by IFNγ further activates transcription of 
TBX21 and IL12Rβ2 (8, 9). We have previously demonstrated 
that naïve human CD4+ T cells do not express the VDR but that 
they start to express it 24–48  h after TCR/CD28 stimulation 
(46, 49). This suggests that vitamin D cannot affect IFNγ pro-
duction in the early stages of T cell activation due to the lack of 
VDR. To study the effect of 25(OH)D3 and Th1-inducing condi-
tions on the early kinetics of VDR expression, we stimulated 
naïve CD4+ T cells for 12, 24, and 48 h in the presence or absence 
of 25(OH)D3 and Th1-inducing conditions. We could confirm 
that only very low levels of VDR are present after 12 and 24 h 
of stimulation, and that substantial VDR expression levels are 
found after 48 h of stimulation (Figure 4A). In agreement, we 
found that at 12 h of stimulation, vitamin D did not influence 
IFNγ production neither in cells activated in the absence or 
presence of Th1 conditions (Figure 4B). In contrast, Th1 condi-
tions acted rapidly with increased production of IFNγ already 
12  h after stimulation (Figure  4B). After 24  h of stimulation, 
a minor inhibitory effect of vitamin D on IFNγ production 
was seen (Figure  4C), and after 48  h vitamin D substantially 
inhibited IFNγ production (Figure  4D). These experiments 
indicated that IL-12-mediated signaling is initiated rapidly 
after initial T cell stimulation with increased IFNγ production 
as a consequence, and that this takes place before the VDR is 
expressed at sufficiently high levels to inhibit IFNγ production. 
These observations support that CD4+ T cells activated under 
Th1-inducing conditions start differentiation toward Th1 cells 
even in the presence of vitamin D.
Vitamin D is required for concomitant 
Production of iFnγ and cathelicidin in 
Dc–T cell co-cultures
Activation of naïve TB-specific T cells depends on the migration 
of infected DC from the lungs to the mediastinal lymph nodes 
where the DC present TB-derived antigens for the T cells (5–7). 
It has been suggested that antigen-presenting cells mediate the 
vitamin D-induced inhibition of IFNγ production in T  cells 
(36, 38, 40), and the absence of antigen-presenting cells in our 
experimental set up could maybe explain why we observed IFNγ 
production in purified T  cells stimulated in the presence of 
vitamin D and IL-12. To investigate this possibility, we cultured 
FigUre 3 | Vitamin D does not prevent Th1 differentiation. Relative TBX21 (a), IL-12Rβ2 (B), and IFNγ (c) expression in T cells activated for 24, 48, or 72 h in 
Th1-polarizing medium in the presence or absence of 100 nM 25(OH)D3. Data are normalized to unstimulated T cells (mean + SEM, n = 6). Representative Western 
blots (lower panel) and quantification (upper panel) of phosphorylated STAT1 and total STAT1 (D) and phosphorylated STAT4 and total STAT4 (e) with GAPDH as 
loading control from T cells activated for 0, 24, 48, and 72 h in Th1-polarizing medium in the presence or absence of 100 nM 25(OH)D3. Western blots including 
protein ladder are shown in the Figure S2 in Supplementary Material.
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naïve CD4+ T cells with allogeneic DC for 6 days with or without 
25(OH)D3 in the absence or presence of Th1-inducing conditions 
and subsequently measured IFNγ expression and production. 
Vitamin D strongly inhibited IFNγ mRNA expression (~15-fold) 
(Figure 5A) and production (~20-fold) (Figure 5B) in the absence 
of Th1-inducing conditions. Th1-inducing conditions increased 
IFNγ expression and production and counteracted the inhibitory 
effect of vitamin D. Thus, vitamin D only inhibited IFNγ mRNA 
expression ~2-fold and IFNγ production ~3-fold in the presence 
of Th1-inducing conditions (Figures 5A,B). Interestingly, IFNγ 
expression and production in cells cultured with vitamin D under 
Th1-inducing conditions were at least as high as in cells cultured 
without vitamin D and Th1-inducing conditions (Figures 5A,B). 
This indicated that DC do not shut down IFNγ production in 
T cells in the presence of vitamin D. Taken together, we could 
conclude that vitamin D strongly inhibits IFNγ expression and 
production in T cells in the absence of Th1-inducing conditions, 
and that Th1-inducing conditions partially rescue IFNγ produc-
tion in the presence of vitamin D independently on the presence 
or absence of DC.
Cellular responses mediated by IFNγ are primarily caused 
by gene expression modulation. Primary IFNγ-responsive 
genes are induced early by binding of STAT1 dimers to gamma-
activating sequences in the promoter of target genes such as 
IRF1, CXCL9, and CXCL10 (50). To study whether the levels 
of IFNγ produced in Th1  cells in the presence of vitamin D 
were sufficient to affect IFNγ-responsive genes, we measured 
the expression of CXCL9 and CXCL10 in the same co-cultures 
as described above. We found that vitamin D reduced CXCL9 
and CXCL10 expression ~110 and ~25-fold in Th0 cells, respec-
tively (Figures  5C,D). In contrast, vitamin D only reduced 
CXCL9 and CXCL10 expression ~2- and ~3-fold in Th1 cells 
compared to untreated Th0 cells. This demonstrated that the 
cellular responses to the levels of IFNγ produced in Th1 cells 
in the presence of vitamin D almost equaled the responses 
to the levels of IFNγ produced in Th0 cells in the absence of 
vitamin D.
As the importance of IFNγ in the immune response to 
mycobacteria is well established, it is puzzling why vitamin D, 
associated with a beneficial role in TB prevention and treatment, 
FigUre 4 | IL-12-mediated signaling is initiated before vitamin D signaling. (a) Representative Western blots (lower panel) and quantification (upper panel) of VDR 
with GAPDH as loading control from T cells activated for 0, 12, 24, and 48 h in the presence or absence of 100 nM 25(OH)D3 and Th1-polarizing medium  
(IL-12 + anti-IL-4) (mean + SEM, n = 2). IFNγ concentration in the supernatants of T cells activated for 12 h (B), 24 h (c), or 48 h (D) in the presence or absence of 
100 nM 25(OH)D3 and Th1-polarizing medium (mean + SEM, n = 4). Western blots including protein ladder are shown in the Figure S3 in Supplementary Material.
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reduces IFNγ production. Cathelicidin plays an important 
role in the killing of especially intracellular pathogens such as 
M. tuberculosis in macrophages (51). Furthermore, it has been 
shown that cathelicidin expression is dependent on vitamin D, 
and that IFNγ increases the synthesis of cathelicidin in mac-
rophages (21–23). To study how cathelicidin is regulated in DC, 
we cultured naïve CD4+ T cells with allogeneic DC for 6 days as 
described above with or without 25(OH)D3 in the absence or 
presence of Th1-inducing conditions and subsequently measured 
cathelicidin expression. We found that cathelicidin upregulation 
was absolutely dependent on vitamin D but independent of Th1-
inducing conditions (Figure 5E). This indicated that vitamin D 
without IFNγ is sufficient to induce cathelicidin upregulation, 
and that IFNγ without vitamin D does not affect cathelicidin 
expression in DC.
Vitamin D counteracts the inhibitory 
effect of M. tuberculosis on cathelicidin 
expression in Dc
Previous studies have demonstrated that IFNγ acts in synergy 
with TLR2 ligands to upregulate cathelicidin expression in 
human monocytes and macrophages (21, 22). To determine how 
vitamin D, IFNγ, and HKMT/TLR2 ligands affect cathelicidin 
expression in DC, we incubated DC in the absence or presence 
of 25(OH)D3, IFNγ, and HKMT or Pam3CSK4, and measured 
the expression of cathelicidin. Surprisingly, we found that 
HKMT and Pam3CSK4 significantly downregulated cathelici-
din expression both in the absence and presence of vitamin D 
(Figure 6A). In contrast, vitamin D strongly upregulated cathel-
icidin expression both in the absence and presence of HKMT or 
Pam3CSK4. Although HKMT and Pam3CSK4 downregulated 
cathelicidin expression ~13- and ~10-fold in the presence of 
vitamin D, respectively, the expression of cathelicidin was still 
~215- and ~120-fold higher in DC stimulated with HKMT/
Pam3CSK4 in the presence of vitamin D than in the absence of 
vitamin D (Figure 6A). IFNγ by itself did not affect cathelicidin 
expression.
To determine whether the HKMT/Pam3CSK4-induced 
inhibition of cathelicidin expression was caused by a reduced 
ability to produce or respond to 1,25(OH)2D3, we incubated 
DC in the absence or presence of 25(OH)D3, IFNγ, and 
HKMT/Pam3CSK4 and measured the expression of CYP27B1, 
VDR, and CYP24A1, and the production of 1,25(OH)2D3. We 
found that HKMT/Pam3CSK4 increased CYP27B1 expres-
sion, especially in the presence of 25(OH)D3 (Figure 6B). In 
FigUre 5 | Vitamin D is required for concomitant production of IFNγ and cathelicidin in DC–T cell cultures. Relative expression (a) and production (B) of IFNγ and 
relative CXCL9 (c), CXCL10 (D), and cathelicidin (e) expression in DC–T cell co-cultures incubated in the presence or absence of 100 nM 25(OH)D3 and  
Th1-polarizing medium (IL-12 + anti-IL-4). Data are normalized to the values obtained from co-cultures incubated in the absence of 25(OH)D3 and Th1-polarizing 
medium (mean + SEM, n = 4).
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accordance, although untreated DC produced high amounts of 
1,25(OH)2D3, HKMT/Pam3CSK4 increased the 1,25(OH)2D3 
production four- to fivefold (Figure 6C). In addition, HKMT 
slightly increased VDR expression in the presence of 25(OH)
D3 (Figure  6D). This suggested that HKMT/Pam3CSK4-
treated DC should be at least as efficient as untreated DC to 
respond to 1,25(OH)2D3. This was supported by the expression 
of comparable levels of the 1,25(OH)2D3/VDR-dependent 
CYP24A1 in DC treated or untreated with HKMT/Pam3CSK4 
in the presence of 25(OH)D3 (Figure 6E). These observations 
indicated that the inhibitory effect of HKMT/Pam3CSK4 
on cathelicidin expression was caused by a vitamin D/VDR-
independent mechanism. To test this hypothesis, we incubated 
DC in the absence or presence of HKMT or Pam3CSK4 and 
increasing concentrations of 1,25(OH)2D3. In all concentra-
tions of 1,25(OH)2D3 tested, we found that HKMT/Pam3CSK4 
inhibited cathelicidin expression (Figure  6F). Interestingly, 
stimulation with the more complex HKMT resulted in a 
~23-fold reduction in cathelicidin expression, whereas the 
pure TLR2 ligand Pam3CSK4 caused an ~8-fold reduction in 
cathelicidin expression at all concentrations of 1,25(OH)2D3 
tested. This suggested that HKMT affected the DC through 
additional receptors than TLR2. In agreement, we found that 
the TLR4 ligand LPS also inhibited cathelicidin expression in 
DC (data not shown). In contrast to the effect on cathelici-
din expression, HKMT/Pam3CSK4 did not affect CYP24A1 
expression, supporting that HKMT/Pam3CSK4 did not inhibit 
the ability of DC to respond to 1,25(OH)2D3/VDR complexes 
(Figure  6G). Taken together, these data indicated that 
M. tuberculosis strongly inhibits cathelicidin expression in DC 
through TLR signaling but that vitamin D increases cathelici-
din expression and thereby more than overcome the inhibitory 
effect of M. tuberculosis.
DiscUssiOn
In this study, we show that vitamin D does not block differen-
tiation of naïve human CD4+ T cells to Th1 cells and that IL-12 
partially rescues IFNγ production in T cells exposed to vitamin D. 
Furthermore, we demonstrate that HKMT/TLR2 ligands strongly 
downregulate cathelicidin expression in DC and that vitamin D 
counteracts this by upregulating cathelicidin expression.
Since the first studies on the effect of vitamin D on IFNγ 
production in human T cells (33, 34) several studies have con-
firmed that vitamin D inhibits IFNγ production in both human 
and mouse T cells (35–46). Some studies found that this was an 
indirect effect mediated via antigen-presenting cells (36, 38, 40), 
whereas others found a direct effect of vitamin D on T  cells 
(41–43). We found that both the inactive and the active form 
of vitamin D inhibit IFNγ production in purified CD4+ T cells. 
Thus, our study confirms that activated T  cells can convert 
inactive vitamin D to active vitamin D, and that vitamin D has 
a direct effect on human T  cells. This is in good accordance 
with expression of both CYP27B1 and the VDR in activated 
FigUre 6 | Vitamin D counteracts the inhibitory effect of M. tuberculosis on cathelicidin production in DC. Relative cathelicidin (a), CYP27B1 (B), VDR (D), and 
CYP24A1 (e) expression and 1,25(OH)2D3 production (c) in untreated DC (no TLR ligand) or DC treated with HKMT or Pam3CSK4 and subsequently incubated for 
24 h in the absence or presence of 100 nM 25(OH)D3 and 10 ng/ml IFNγ. Data are normalized to the values obtained from untreated DC in the absence of 25(OH)D3 
and IFNγ (mean + SEM, n ≥ 3), *indicates p ≤ 0.05. Relative cathelicidin (F) and CYP24A1 (g) expression in untreated DC (no TLR ligand) or DC treated with HKMT 
or Pam3CSK4 incubated for 24 h with the indicated concentrations of 1,25(OH)2D3. Data are normalized to untreated DC in the absence of 1,25(OH)2D3 
(mean ± SEM, n ≥ 3), * indicates p ≤ 0.05 for no TLR ligand untreated versus 1,25(OH)2D3 treated, # indicates p ≤ 0.05 for HKMT versus no TLR ligand, ¤ indicates 
p ≤ 0.05 for Pam3CSK4 versus no TLR ligand.
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human T  cells (46, 47, 49, 52). Based on the impaired IFNγ 
production and increased IL-4 production in T cells exposed to 
vitamin D, it has been concluded that vitamin D restrains Th1 
differentiation and promotes Th2 differentiation. However, only 
few studies have investigated whether vitamin D actually affects 
the master transcription factors TBX21 and GATA3 regulating 
Th1 and Th2 differentiation. One study found that although 
1,25(OH)2D3 inhibited IFNγ production, it had no effect on 
the levels of TBX21 and GATA3 in mouse T  cells activated 
under Th0, Th1, or Th2 conditions (37). Another study found 
a very discrete increase in GATA3 expression in mouse T cells 
activated in the presence of 1,25(OH)2D3 under Th0 conditions, 
but they did not study TBX21 expression nor the effect of Th1 
conditions (53). We found that vitamin D did not significantly 
affect the expression of TBX21 in human T cells activated under 
Th1 conditions. Likewise, although IL-12Rβ2 upregulation was 
slightly inhibited at 24  h, vitamin D did not affect IL-12Rβ2 
expression at later time points. This indicated that vitamin D 
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does not restrain Th1 differentiation. STAT4 and STAT1 sign-
aling play critical roles in the differentiation of Th1  cells (8). 
We are not aware of previous studies that have investigated the 
effect of vitamin D on STAT1 and STAT4 activation in human 
T cells. In the present study, we found that vitamin D did not 
significantly affect phosphorylation of STAT1 and STAT4 in 
T cells activated under Th1 conditions, which further supports 
that vitamin D does not block differentiation of Th1  cells. 
Thus, vitamin D most likely directly affects transcription of the 
IFNG gene and not the differentiation of naïve CD4+ T cells to 
Th1  cells. This is in accordance with previous studies, which 
found that 1,25(OH)2D3/VDR complexes directly bind to the 
IFNG promoter and inhibit IFNG transcription (54) and that 
the fraction of IFNγ-producing T cells is not reduced in T cells 
activated in the presence of vitamin D under Th1 conditions 
(55). The kinetic studies illustrated in Figures 3 and 4 in this 
study also strongly support that vitamin D does not inhibit 
Th1 differentiation. The VDR is not or only weakly expressed 
in T  cells for the first 24  h of stimulation, and consequently 
vitamin D cannot affect IFNγ expression or production at these 
early time points. In contrast, IL-12 signaling is efficient already 
shortly after T  cell activation and augments IFNγ production 
and initiates Th1 differentiation.
It has been demonstrated that the promoter of the human 
cathelicidin gene contains a consensus vitamin D response ele-
ment, and that cathelicidin is upregulated by vitamin D (56, 57). 
Shortly after these studies, it was found that signaling through 
TLR2 induced upregulation of CYP27B1 and the VDR in human 
monocytes and macrophages but not in DC (24). Furthermore, 
upregulation of cathelicidin and growth inhibition of M. tuber-
culosis were seen if the cell culture media was supplemented 
with 25(OH)D3 (24). A subsequent study confirmed that the 
vitamin D-mediated antimicrobial activity against M. tubercu-
losis in the human monocytic cell line THP-1 was dependent 
on cathelicidin (51). In accordance with Liu et  al. (24), we 
found that HKMT/TLR2 triggering did not significantly affect 
VDR expression in DC. In contrast to VDR, we found that the 
TLR2 ligand Pam3CSK4 and especially HKMT upregulated 
CYP27B1 expression and 1,25(OH)2D3, production in the 
presence of 25(OH)D3. However, although HKMT/Pam3CSK4 
upregulated CYP27B1, untreated DC still expressed high levels 
of CYP27B1. Accordingly, we found that even untreated DCs 
have a high capacity to convert 25(OH)D3 to 1,25(OH)2D3, 
and to respond to 1,25(OH)2D3 with strong upregulation of 
cathelicidin and CYP24A1 expression. In sharp contrast to 
studies finding that TLR2 ligands upregulated cathelicidin in 
human monocytes and macrophages in a vitamin D-dependent 
manner (21, 22, 24), we found that HKMT profoundly 
downregulated cathelicidin in human DC. Although HKMT 
is described as a primary TLR2 ligand, it has been reported 
that M. tuberculosis stimulates a range of other receptors, 
including TLR4 and 9 (10). However, we found that the TLR2 
ligand Pam3CSK4 mimicked HKMT in regard to cathelicidin 
downregulation, although not quite as efficiently as HKMT. 
TLR4 triggering also resulted in cathelicidin downregulation 
and we could conclude that M. tuberculosis can downregulate 
cathelicidin expression in DC through signaling via TLR2 and 
most likely additional TLR. As for cathelicidin expression, 
different responses between monocytes/macrophages and DC 
to TLR2 signaling have been reported concerning MHC class 
II expression. Thus, whereas TLR2 signaling inhibits MHC 
class II expression in macrophages, it enhances MHC class II 
expression in DC (58). Interestingly, although the paradigm 
is that TLR2 signaling increases cathelicidin expression in 
human monocytes and macrophages (21, 22, 24), two papers 
have actually found that TLR2 signaling reduces cathelicidin 
expression in human monocytes in accordance with what we 
find in human DC (59, 60).
M. tuberculosis uses various strategies to evade antimicrobial 
mechanisms of macrophages, including inhibition of phagosome–
lysosome fusion, antigen presentation, MHC class II expression, 
autophagy, and cytokine production (61). Interestingly, many of 
these immune evasion mechanisms are driven by TLR2 signal-
ing (62–65). In the present study, we show that HKMT can use 
TLR2 signaling to strongly inhibit cathelicidin expression in DC, 
and as for autophagy (22, 24), we find that this attempt to evade 
the immune system by M. tuberculosis can be counteracted by 
vitamin D. Thus, although vitamin D reduces IFNγ production, 
we could conclude that vitamin D does not block Th1 develop-
ment, and that Th1 cells produce significant amounts of IFNγ in 
the presence of vitamin D. At the same time, vitamin D is required 
to upregulate and counteract downregulation of cathelicidin by 
M. tuberculosis. We believe that these findings add to the under-
standing of the beneficial role of vitamin D in TB prevention and 
treatment.
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